Ascletis says ASC50 cuts PASI score 48.9% in 28-day U.S. psoriasis study

The trial was a 28-day U.S. proof-of-concept study in plaque psoriasis. Ascletis said effects continued beyond the final dose and no serious events or liver-related signals were reported.